AGC Biologics Capacity Update February 2024: Cell & Gene

AGC Biologics is a global end-to-end cell and gene CDMO that has a scientific team with 25+ years of experience, one of the most impressive track records in the industry. In this presentation from the February 2024 OPCU event, learn more about the AGC Biologics’ global Cell and Gene network, track record, capabilities, and how it can provide support for any project. This presentation also provides a detailed look at the North American site in Longmont, Colorado, which specializes in both cell and viral vector gene therapy projects.

Join AGC Biologics for an in-depth look at this 622,000 sq ft. campus, including our recently expanded cell therapy suites and added flexible fill/finish capabilities, GMP vector manufacturing, and our full lifecycle process development and manufacturing capabilities, hosted by our Director of MSAT for Cell and Gene Therapy, Jeff Rosenbloom.